Trial reportInternational ophthalmology2026
High dose versus low dose Mitomycin-C assisted bleb needling in failing trabeculectomy blebs: a prospective comparative study.
Trial report in International ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo compare the safety and efficacy of high dose versus low dose Mitomycin-C (MMC) for bleb needling in failing trabeculectomy blebs.
methodsPatients (> 18 years) who did not achieve target intraocular pressure (IOP) and/or required anti glaucoma medications (AGMs) post trabeculectomy were recruited in this prospective, comparative, interventional study between December 2023-January 2025. MMC augmented bleb needling was performed with random allocation of patients to Group A (high dose MMC-60 μg) and Group B (low dose MMC-20 μg). Primary outcome was "complete success" (IOP 6-18 mmHg or IOP reduction > 20% without AGMs) and "qualified success" (criteria for complete success achieved with AGMs). Secondary outcome included bleb morphological changes on anterior segment optical coherence tomography (ASOCT), factors associated with success and complication rate.
resultsA total of 54 patients underwent MMC augmented bleb needling (27 in each group). Baseline parameters were comparable between the groups. IOP decreased significantly from baseline (Group A-26.9 ± 5.3 mmHg; Group B-27.0 ± 4.9 mmHg) to 6 months (Group A -13.39 ± 2.6 mmHg; Group B-13.62 ± 1.7 mmHg) in both the groups and was maintained at 1 year (Group A: 12.72 ± 1.69 mmHg; Group B: 12.61 ± 1.89 mmHg). Complete success was higher in Group A compared to Group B (44.4% vs. 18.5%; p = 0.04) at 6 months and 1 year (35% vs. 5%; p = 0.04). Bleb assessment on ASOCT revealed decrease in internal reflectivity of bleb wall, and increase in bleb wall height and bleb wall thickness. Adverse events included subconjunctival hemorrhage (68.5%; n = 37/54), hypotony (3.7%; n = 2/54), hyphema (3.7%; n = 2/54) and conjunctival buttonhole (1.85%; n = 1/54) which were comparable between the two groups.
conclusionBleb needling with high dose MMC is a safe and effective measure for reviving failing trabeculectomy blebs with no added adverse outcomes when compared to low dose MMC. ASOCT effectively correlates bleb structure changes with post-operative IOP control.
Indexed as
Identifiers
42171827What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.